Brigatinib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-BRIGATINIB |
|---|---|
| Type | Drug |
| Aliases | AlunbrigБригатиніб |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Drug Facts
| Class | 2nd-generation ALK inhibitor |
|---|---|
| Mechanism | ALK / ROS1 inhibitor with broad-spectrum activity vs ALK resistance mutations. ALTA-1L: superior PFS vs crizotinib 1L. |
| Typical dosing | 180 mg PO once daily after 7-day lead-in at 90 mg. |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
Alternative to alectinib 1L with similar efficacy; choice often based on AE profile preference.
Used By
No reverse references found in the YAML corpus.